INTRODUCTION
The major consequence of poor glycemic control in people with diabetes is chronic hyperglycemia [1] , which can lead to a large number of microvascular and macrovascular issues. One common microvascular condition is foot ulceration, which results from diabetic neuropathy and vascular complications. The risk of developing neuropathy is directly proportional to both the duration and magnitude of hyperglycemia [2] , and therefore, maintaining glycemic control is vital to reduce the number of foot ulcers.
There are mixed data on the prevalence of foot ulcers, but estimations as high as 25% of patients with diabetes being affected over their lifetime, have been made [3] . The management of the condition is complex as a large proportion will fail to heal, and there is an increased risk of serious infection and extremity amputation [4] . Therefore, the condition is a significant financial burden on the National Health Service (NHS), through outpatient costs, increased bed occupancy and prolonged hospital stays [5] . The size of this burden is highlighted by a report by Hex and colleagues [6] , who estimated the cost of foot ulcers and amputations to the NHS to be £985 m in 2010/2011, the most expensive category of diabetes complications.
There is a well-established link between uncontrolled or high glycated hemoglobin (HbA1c) levels and clinical complications [7] . As such, it is important to keep HbA1c levels stable to reduce the risk of these complications, with guidance in the UK stating that HbA1c should be kept at a level of 6.5% (48 mmol/mol) or below in people with type 1 diabetes, and between 6.5% and 7% (48-53 mmol/mol) in people with type 2 diabetes [8, 9] . However, in practice, patients often fail to achieve suitable HbA1c levels, as shown by a survey in Sweden that found only less than one-third of insulin-treated patients with type 2 diabetes to havereached the recommended HbA1c goal of \7% (53 mmol/mol), over 6 years [10] . Overall, there is mixed evidence regarding the mean HbA1c level among the diabetes population. However, two large-scale meta-analyses of diabetes-related interventions found that, among participants, baseline HbA1c was 8.05% and 8.13%, indicating that mean levels are likely to be at least 8% (64 mmol/mol) [11, 12] .
Insulin therapy is seen as an important treatment option for both type 1 and type 2 diabetes [13, 14] . Administration is commonly achieved via manual insulin injection or insulin pumps, supported by self-monitoring of blood glucose. However, this method has been used for many years, and the problem of poor glycemic control remains. This issue is highlighted by a paper by Simmons and colleagues [15] , which found that 63% of pump users (916 participants) and 70% of injection users (978 participants) had a HbA1c of 8.5% (69 mmol/mol) or greater. More effective glycemic control can be achieved using an insulin titration protocol. These protocols allow for more sensitive adjustments in insulin doses, leading to both near-normal glucose readings and the avoidance of hypoglycemic events [16] . However, insulin titration is complex, so achieving these goals is a difficult task. The difficulty largely arises as adjustments to insulin dosage must currently be undertaken with the assistance of a physician.
However, visits usually occur every 3-6 months, making the system of titration unresponsive to short-term changes in blood glucose. Bastyr and colleagues [17] analyzed the impact of intensive insulin therapy, accompanied by monitoring using an electronic diary. The study found that 
METHODS

Population
The target population for this analysis was patients with diabetes currently treated by the UK NHS who are at high risk of foot ulcers, defined as those who have a HbA1c of 9% or greater (74.9 mmol/mol). HbA1c is the main driver as it has been established that it directly influences both the healing rate for foot ulcers and the rate of wound recurrence [18, 19] . Two patient groups were included: those receiving d-Nav to control HbA1c (i.e., the treatment group), and those receiving current standard NHS diabetes care (i.e., the control group). For this analysis, NHS standard care is defined as the administration of insulin via injection or pumps and accompanied by self-monitoring of blood glucose. In practice, patients with Guidance System has been designed to optimize patients' insulin dosage regimens through the use of algorithms that identify patterns in time-lagged glucose readings and adjust insulin dosage accordingly. This is achieved using a handheld device (d-Nav), which is shown here, and is supported by a nurse-based service to ensure good use diabetes would receive a greater range of therapies, but this distinct population has been chosen here, as these are the patients most applicable to the d-Nav service. The underlying HbA1c for patients in both groups was determined by a single-arm observational study, which examined the effectiveness of d-Nav to improve glycemic control [20] . This was a single-center evaluation in which 122 patients were trained to use d-Nav as part of their usual treatment protocol and, then, HbA1c with d-Nav remained stable at 7-7.5% over three years [21] . This data was presented after this analysis was completed, and therefore, the data were not formally included. To more accurately model the glycemic level of patients, these mean and standard deviation values were used to estimate the distribution of patients across six HbA1c levels (\6%, 6-7%, 7-8%, 8-9%, 9-10%, and [10%). A normal distribution was assumed.
The number of patients in each level, for both the treatment and control groups, is shown in Fig. 3 . 
Model Structure
The cost-effectiveness of d-Nav was determined using a Markov model (Fig. 4) , which was constructed using Microsoft Excel (Microsoft Corporation, Redmond, WA, USA). Markov models are commonly used in economic evaluations to model long-term patient outcomes and are particularly applicable for progressive chronic conditions such as diabetes. Within Markov models, patients are allocated to predefined health 'states', with each state associated with specific costs and health outcomes. The current model contained four health states: no ulcer, uninfected ulcer, infected ulcer and amputation. Markov models operate in cycles, which cover a discrete time period (e.g., 1 month, 1 year), with weekly cycles adopted here. Patients remain in a set health state for one cycle and can transition to a separate state at the end of each cycle.
Transition probabilities are used to predict patient movement between health states; for example, if a patient is treated with a more efficacious intervention, they will have a lower Therefore, mortality was not considered.
Transition Probabilities
Movement between the health states was governed by transition probabilities, which were taken from the wider literature (Table 1 ).
Due to the short timeframe used, these probabilities were not time-dependent. HbA1c directly influences both the healing rate and the rate of wound recurrence for foot ulcers.
Christman et al. [18] stratified 183 individuals with diabetes into three HbA1c groups (\7%, 7-8%, and [8%) and investigated the change in wound area (cm 2 per day). The investigators found that, for each 1% point increase in
HbA1c, daily change in wound area decreased by 0.022 cm 2 (P = 0.027). They concluded that glycemic control is directly correlated with the healing rate for foot ulcers. In the model, daily change in wound area was converted to daily healing rate by dividing the change in area by the baseline area size for each of the three HbA1c categories. These healing rates were then converted to weekly transition probabilities, using the equation outlined in Fig. 5 and applied to each of the six HbA1c levels discussed previously. The HbA1c categories used in the model did not perfectly match those assessed by Christman et al. [18] . Therefore, the healing rate for patients with
HbA1c \7% was applied to both \6% and 6-7% patients, while the healing rate for patients with
HbA1c
[8% was applied to 8-9%, 9-10%, and [10% patients.
Dubský et al. [19] followed 73 patients with diabetes over a 3-year time period to examine the frequency of, and risk factors for, foot ulcer A number of input parameters were utilized in the model to predict long-term patient outcomes. These parameters are summarized below, along with the source of the information. Where applicable, rates were converted to probabilities to make the data applicable to the model structure adopted for the analysis. Both the original rate and subsequent transition probability are presented recurrence, with HbA1c being significantly associated with the risk of ulceration recurrence. Using data from the paper by Dubský et al. [19] , it was estimated that the 3-year risk of recurrence was 33.3% for patients with HbA1c \7.5% and 67.3% for patients with HbA1c [7.5%. These rates were applied to the patient distributions to generate predicted 3-year healing rates. To be suitable for the Markov model, these healing rates were also converted to transition probabilities (Fig. 5) . Rate of infection, healing rate for infected ulcers and risk of amputation were also required. These parameters were not linked to patient HbA1c due to a deficiency in relevant data from the wider literature. Therefore, transition probabilities were estimated from relevant values identified in a targeted literature search and applied equally across all HbA1c groups.
Costs and Resource Use
Where necessary, costs were inflated to 2013/14 prices using the hospital and community health services index [23] . The insulin regimen considered in this analysis is once-daily Table 2 ). It was assumed that 100% of control group patients used a blood glucose monitoring device, in line with the patient population deemed most applicable for d-Nav, and they self-tested, on average, three times per day at a mean cost of £14.57 for 50 test strips [24] . This was combined with an average cost of £3.42 for 100 lancets equating to a weekly cost of £6.84 [25] . The cost of the d-Nav service is altered depending on the total number of users within each population, as outlined in Table 3 .
Patients also incurred costs depending on the health state within which they resided (Table 3) . These health state costs were sourced from the literature [4] and applied to weekly cycles.
Utility
To estimate the impact of treatment on patient health-related quality of life, quality-adjusted life year (QALY) scores were calculated using utility values. Utility is a measurement of patient's preferences for different health p = 1 -e Ln(1-r/t) where:
p is the transition probability r is the event rate t is the time period of the overall cohort). Second, a scenario was created in which the distribution of control patients' HbA1c levels was fixed, so that all patients had a HbA1c of C9%. This is the optimal population to be targeted with the intervention.
Evaluation
Costs and utility values used in the model were both discounted at a rate of 3.5%, in line Metformin/Pioglitazone £10.65 [31] Metformin/Vildagliptin £9.64 [31] Metformin/Sitagliptin £10.26 [31] Metformin/Linagliptin £9.52 [31] Insulin regimens Lantus Ò (long-acting) £30.68 per 1000 units [30] with guidance issued by the National Institute for Health and Care Excellence (NICE) for its technology appraisal program [27] . To determine the cost-effectiveness of the treatment from a societal perspective, a willingness-to-pay threshold was adopted.
Within the model, a cost per QALY threshold of £20,000 was applied, the lower value of the range formally adopted by NICE [27] . This threshold was used to generate net monetary benefit values with positive values indicating cost-effectiveness at the chosen threshold.
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RESULTS
In the analysis, d-Nav was estimated to be cost saving (-£1278) and produced more QALYs (0.009) than standard care with a total monetary net benefit value of £1459 per patient.
The univariate sensitivity analysis is summarized in Fig. 6 savings. Treatments that improve glycemic control are estimated to be cost-effective due to the reduction in the incidence of foot ulcers and amputations. This leads to savings as fewer resources are required to treat the underlying conditions. Furthermore, there is a reduction in the number of prescriptions for anti-diabetic agents and blood glucose monitoring devices and test strips and an improvement in patient's quality of life. Given the scale of the burden caused by diabetic foot ulcers, implementing interventions, such as d-Nav, has the potential to generate substantial benefits to the healthcare system. It is important to note that this analysis focused solely on outcomes relating to foot ulcers. However, by improving glycemic control, patients with diabetes and the wider healthcare system are also likely to benefit from a reduction in the incidence of other diabetic complications (e.g., stroke, retinopathy), and the magnitude of these benefits could be significant.
Based on the sensitivity analysis that was undertaken, the model results appear to be relatively robust to changes in underlying parameters. The results are most sensitive to changes in the patient HbA1c, which is unsurprising as the model outcomes are largely driven by the reduction in HbA1c facilitated by d-Nav. This also indicates that interventions are best targeted at patients with very high ([9%) HbA1c levels.
The HbA1c values, which are the main drivers of the model, are taken from a single-arm study. Ideally, HbA1c would be based on a large-scale, randomized trial that quantifies the difference in HbA1c between patients using standard care and those enrolled on the d-Nav service. However, in this instance, the lack of a control group should not be considered a major limitation, because it is reasonable to use patient HbA1c at study baseline as the value used for the control group in the model. This is because the value adopted in the analysis is representative of the wider, high-risk population that should be targeted with interventions to improve glycemic control.
The second limitation with the model is that, within the control group, it is assumed that the mean HbA1c remains at [9% throughout the full time horizon. In reality, some patients may show improvement; particularly if their treatment regimen is altered (e.g., they are moved onto continuous blood glucose monitoring). However, in clinical practice, a large number of patients will not alter their lifestyle or treatment and, therefore, are likely to remain with unstable HbA1c levels.
It is these patients that d-Nav should be targeted at and the ones that are considered in this analysis.
Although the association between HbA1c
and diabetic complications is well established, there appears to be a deficit in the research that has been undertaken to quantify the relationship between glycemic control and neuropathy. Therefore, HbA1c could not be linked to the rate of infection, the healing rate for infected ulcers, or the rate of amputation; following a targeted literature search. In reality, patients with HbA1c within recommended ranges are likely to have lower rates for each of these parameters and, thus, improved outcomes overall. It is, therefore, unfortunate that this link could not be quantified in this analysis, and more clinical evaluations are needed to rectify the issue. Furthermore, a target review of the literature was undertaken, and while comprehensive, it may not have captured all available evidence. Therefore, a formal systematic literature review would strengthen the analysis if undertaken.
CONCLUSIONS
The analysis undertaken here indicates that interventions targeted at patients with diabetes with poor glycemic control, such as d-Nav, may be cost-effective in the prevention and management of neuropathic foot ulcers.
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